HAPPENING NOW
Health
Low-cost treatment for multiple sclerosis shown to be as effective as standard therapy
A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-deplet…
AI Summary
A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B-cell-depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS). The study, known as OVERLORD-MS, is the first randomized, double-blind, head-to-head trial comparing the two therapies in ea…
Read full article on MedicalxpressAI summaries can be wrong sometimes—always verify important details using the source article.
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNow